Focused On-demand Library for AP-4 complex subunit mu-1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

O00189

UPID:

AP4M1_HUMAN

Alternative names:

AP-4 adaptor complex mu subunit; Adaptor-related protein complex 4 subunit mu-1; Mu subunit of AP-4; Mu-adaptin-related protein 2; Mu4-adaptin

Alternative UPACC:

O00189; D6W5U1; Q8WV65; Q9UHK9

Background:

AP-4 complex subunit mu-1, also known as Adaptor-related protein complex 4 subunit mu-1, plays a crucial role in vesicle formation and cargo selection. It is a component of the adaptor protein complex 4 (AP-4), which is involved in the vesicular transport of proteins across different trafficking pathways. This protein is essential for the targeting of proteins from the trans-Golgi network (TGN) to the endosomal-lysosomal system and plays a role in protein sorting to the basolateral membrane in epithelial cells.

Therapeutic significance:

AP-4 complex subunit mu-1 is linked to Spastic paraplegia 50, a neurodegenerative disorder. Understanding the role of AP-4 complex subunit mu-1 could open doors to potential therapeutic strategies for treating this condition.